IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-46296-7.html
   My bibliography  Save this article

Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2

Author

Listed:
  • Dongtak Lee

    (Korea University
    Brigham and Women’s Hospital
    Harvard Medical School)

  • Hyo Gi Jung

    (Korea University
    Korea University)

  • Dongsung Park

    (Korea University
    Kyung Hee University)

  • Junho Bang

    (Korea University
    Korea University)

  • Da Yeon Cheong

    (Korea University
    Korea University)

  • Jae Won Jang

    (Korea University
    Korea University)

  • Yonghwan Kim

    (Korea University
    Korea University)

  • Seungmin Lee

    (Korea University
    Kwangwoon University)

  • Sang Won Lee

    (Korea University
    Terasaki Institute for Biomedical Innovation)

  • Gyudo Lee

    (Korea University
    Korea University)

  • Yeon Ho Kim

    (Korea University
    Korea University)

  • Ji Hye Hong

    (Korea University
    Kwangwoon University)

  • Kyo Seon Hwang

    (Kyung Hee University)

  • Jeong Hoon Lee

    (Kwangwoon University)

  • Dae Sung Yoon

    (Korea University
    Korea University
    Astrion Inc)

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has evoked a worldwide pandemic. As the emergence of variants has hampered the neutralization capacity of currently available vaccines, developing effective antiviral therapeutics against SARS-CoV-2 and its variants becomes a significant challenge. The main protease (Mpro) of SARS-CoV-2 has received increased attention as an attractive pharmaceutical target because of its pivotal role in viral replication and proliferation. Here, we generated a de novo Mpro-inhibitor screening platform to evaluate the efficacies of Mpro inhibitors based on Mpro cleavage site-embedded amyloid peptide (MCAP)-coated gold nanoparticles (MCAP-AuNPs). We fabricated MCAPs comprising an amyloid-forming sequence and Mpro-cleavage sequence, mimicking in vivo viral replication process mediated by Mpro. By measuring the proteolytic activity of Mpro and the inhibitory efficacies of various drugs, we confirmed that the MCAP-AuNP-based platform was suitable for rapid screening potential of Mpro inhibitors. These results demonstrated that our MCAP-AuNP-based platform has great potential for discovering Mpro inhibitors and may accelerate the development of therapeutics against COVID-19.

Suggested Citation

  • Dongtak Lee & Hyo Gi Jung & Dongsung Park & Junho Bang & Da Yeon Cheong & Jae Won Jang & Yonghwan Kim & Seungmin Lee & Sang Won Lee & Gyudo Lee & Yeon Ho Kim & Ji Hye Hong & Kyo Seon Hwang & Jeong Hoo, 2024. "Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46296-7
    DOI: 10.1038/s41467-024-46296-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-46296-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-46296-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Dongtak Lee & Dongsung Park & Insu Kim & Sang Won Lee & Wonseok Lee & Kyo Seon Hwang & Jeong Hoon Lee & Gyudo Lee & Dae Sung Yoon, 2021. "Plasmonic nanoparticle amyloid corona for screening Aβ oligomeric aggregate-degrading drugs," Nature Communications, Nature, vol. 12(1), pages 1-11, December.
    2. Zhenming Jin & Xiaoyu Du & Yechun Xu & Yongqiang Deng & Meiqin Liu & Yao Zhao & Bing Zhang & Xiaofeng Li & Leike Zhang & Chao Peng & Yinkai Duan & Jing Yu & Lin Wang & Kailin Yang & Fengjiang Liu & Re, 2020. "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors," Nature, Nature, vol. 582(7811), pages 289-293, June.
    3. Taniya Bhardwaj & Kundlik Gadhave & Shivani K. Kapuganti & Prateek Kumar & Zacharias Faidon Brotzakis & Kumar Udit Saumya & Namyashree Nayak & Ankur Kumar & Richa Joshi & Bodhidipra Mukherjee & Aparna, 2023. "Amyloidogenic proteins in the SARS-CoV and SARS-CoV-2 proteomes," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    4. Britton Boras & Rhys M. Jones & Brandon J. Anson & Dan Arenson & Lisa Aschenbrenner & Malina A. Bakowski & Nathan Beutler & Joseph Binder & Emily Chen & Heather Eng & Holly Hammond & Jennifer Hammond , 2021. "Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    5. Kangsa Amporndanai & Xiaoli Meng & Weijuan Shang & Zhenmig Jin & Michael Rogers & Yao Zhao & Zihe Rao & Zhi-Jie Liu & Haitao Yang & Leike Zhang & Paul M. O’Neill & S. Samar Hasnain, 2021. "Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives," Nature Communications, Nature, vol. 12(1), pages 1-7, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lisa-Marie Funk & Gereon Poschmann & Fabian Rabe von Pappenheim & Ashwin Chari & Kim M. Stegmann & Antje Dickmanns & Marie Wensien & Nora Eulig & Elham Paknia & Gabi Heyne & Elke Penka & Arwen R. Pear, 2024. "Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    2. Hengrui Liu & Sho Iketani & Arie Zask & Nisha Khanizeman & Eva Bednarova & Farhad Forouhar & Brandon Fowler & Seo Jung Hong & Hiroshi Mohri & Manoj S. Nair & Yaoxing Huang & Nicholas E. S. Tay & Sumin, 2022. "Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    3. Nik Franko & Ana Palma Teixeira & Shuai Xue & Ghislaine Charpin-El Hamri & Martin Fussenegger, 2021. "Design of modular autoproteolytic gene switches responsive to anti-coronavirus drug candidates," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    4. Jaeyong Lee & Calem Kenward & Liam J. Worrall & Marija Vuckovic & Francesco Gentile & Anh-Tien Ton & Myles Ng & Artem Cherkasov & Natalie C. J. Strynadka & Mark Paetzel, 2022. "X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    5. Zeyin Yan & Dacong Wei & Xin Li & Lung Wa Chung, 2024. "Accelerating reliable multiscale quantum refinement of protein–drug systems enabled by machine learning," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    6. Xiangrui Jiang & Haixia Su & Weijuan Shang & Feng Zhou & Yan Zhang & Wenfeng Zhao & Qiumeng Zhang & Hang Xie & Lei Jiang & Tianqing Nie & Feipu Yang & Muya Xiong & Xiaoxing Huang & Minjun Li & Ping Ch, 2023. "Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    7. Ella Borberg & Eran Granot & Fernando Patolsky, 2022. "Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CLpro enzymatic activity in untreated saliva samples," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    8. Tetsuro Matsunaga & Hirohito Sano & Katsuya Takita & Masanobu Morita & Shun Yamanaka & Tomohiro Ichikawa & Tadahisa Numakura & Tomoaki Ida & Minkyung Jung & Seiryo Ogata & Sunghyeon Yoon & Naoya Fujin, 2023. "Supersulphides provide airway protection in viral and chronic lung diseases," Nature Communications, Nature, vol. 14(1), pages 1-25, December.
    9. Rana Abdelnabi & Caroline S. Foo & Dirk Jochmans & Laura Vangeel & Steven De Jonghe & Patrick Augustijns & Raf Mols & Birgit Weynand & Thanaporn Wattanakul & Richard M. Hoglund & Joel Tarning & Charle, 2022. "The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    10. Norman Tran & Sathish Dasari & Sarah A. E. Barwell & Matthew J. McLeod & Subha Kalyaanamoorthy & Todd Holyoak & Aravindhan Ganesan, 2023. "The H163A mutation unravels an oxidized conformation of the SARS-CoV-2 main protease," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    11. Rana Abdelnabi & Dirk Jochmans & Kim Donckers & Bettina Trüeb & Nadine Ebert & Birgit Weynand & Volker Thiel & Johan Neyts, 2023. "Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment," Nature Communications, Nature, vol. 14(1), pages 1-7, December.
    12. Mohammad (Behdad) Jamshidi & Omid Moztarzadeh & Alireza Jamshidi & Ahmed Abdelgawad & Ayman S. El-Baz & Lukas Hauer, 2023. "Future of Drug Discovery: The Synergy of Edge Computing, Internet of Medical Things, and Deep Learning," Future Internet, MDPI, vol. 15(4), pages 1-15, April.
    13. Ala M. Shaqra & Sarah N. Zvornicanin & Qiu Yu J. Huang & Gordon J. Lockbaum & Mark Knapp & Laura Tandeske & David T. Bakan & Julia Flynn & Daniel N. A. Bolon & Stephanie Moquin & Dustin Dovala & Nese , 2022. "Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    14. Daniel W. Kneller & Hui Li & Gwyndalyn Phillips & Kevin L. Weiss & Qiu Zhang & Mark A. Arnould & Colleen B. Jonsson & Surekha Surendranathan & Jyothi Parvathareddy & Matthew P. Blakeley & Leighton Coa, 2022. "Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    15. Maki Kiso & Seiya Yamayoshi & Shun Iida & Yuri Furusawa & Yuichiro Hirata & Ryuta Uraki & Masaki Imai & Tadaki Suzuki & Yoshihiro Kawaoka, 2023. "In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir," Nature Communications, Nature, vol. 14(1), pages 1-8, December.
    16. Federico Iacovelli & Gaetana Costanza & Alice Romeo & Terenzio Cosio & Caterina Lanna & Antonino Bagnulo & Umberto Di Maio & Alice Sbardella & Roberta Gaziano & Sandro Grelli & Ettore Squillaci & Ales, 2022. "Interaction of Pelargonium sidoides Compounds with Lactoferrin and SARS-CoV-2: Insights from Molecular Simulations," IJERPH, MDPI, vol. 19(9), pages 1-22, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46296-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.